Risk of Acute GVHD

GVHD (graft‑versus‑host disease) is a major complication that occurs within 100 days after allogeneic hematopoietic stem cell transplantation, primarily affecting the skin, gastrointestinal tract, and liver. Haploidentical transplants, especially from female donors, carry a higher risk of grade ≥ II acute GVHD. Current prophylaxis agents—including calcineurin inhibitors, methotrexate, mycophenolate, and PTCy—have not sufficiently reduced this risk.

Mechanism of Action of the JAK1 Inhibitor Ivarmacitinib

JAK1‑dependent cytokine signaling (e.g., IL‑6, IFN‑γ) drives T‑cell activation and inflammation. Ivarmacitinib (SHR0302) is a highly selective oral JAK1 inhibitor that suppresses inflammatory cytokine production while preserving hematopoiesis. These properties are considered ideal for preventing acute GVHD.

Clinical Trial Design and Current Status

The study is a Phase 2, recruiting trial co‑sponsored by Shanghai General Hospital and Shanghai Jiao Tong University School of Medicine. It evaluates the incidence of acute GVHD in haplo‑PBSCT patients receiving low‑dose ATG/PTCy in combination with Ivarmacitinib. Detailed primary endpoints and patient eligibility criteria are listed in the ClinicalTrials.gov registration.

Differentiation from Existing Prophylactic Strategies

Current standard prophylaxis combines immunosuppressants with cytotoxic agents, which can suppress hematopoiesis and increase infection risk. Ivarmacitinib’s selective JAK1 blockade may modulate immune responses while minimizing hematopoietic suppression. Moreover, its oral formulation is expected to improve patient convenience.

Potential Impact if Successful

If this regimen markedly reduces acute GVHD, the safety profile of haploidentical transplantation would improve, potentially expanding the global use of haplo‑HSCT. It would also add a new indication to the JAK1 inhibitor market, likely enhancing the valuation of companies that own this platform technology.